WS Investor
17 Mar 2026, 22:22
Pfizer Reports Positive Phase 2 Results for Next-Generation Breast Cancer Drug
Pfizer announced positive topline Phase 2 results for its investigational CDK4 inhibitor atirmociclib in patients with advanced or metastatic breast cancer.
The FOURLIGHT-1 study met its primary endpoint, showing a 40% reduction in the risk of disease progression or death compared to standard treatments, with a manageable safety profile. The results support further development of atirmociclib as a potential next-generation therapy, with ongoing Phase 3 trials in earlier treatment settings.
Business Wire
Pfizer announced positive topline Phase 2 results for its investigational CDK4 inhibitor atirmociclib in patients with advanced or metastatic breast cancer.
The FOURLIGHT-1 study met its primary endpoint, showing a 40% reduction in the risk of disease progression or death compared to standard treatments, with a manageable safety profile. The results support further development of atirmociclib as a potential next-generation therapy, with ongoing Phase 3 trials in earlier treatment settings.
Business Wire